S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition

Breast Cancer Research and Treatment

Volumn 127, Issue 1, 2011, Pages 109-119

  Hayden, Annette ^a   Johnson, Peter W M ^a   Packham, Graham ^a   Crabb, Simon J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

3 Deazaneplanocin A; Breast cancer; Enhancer of zeste homolog 2; Histone deacetylase inhibitor; S adenosylhomocysteine hydrolase; Trastuzumab

Indexed keywords

3 DEAZAADENOSINE; 3 DEAZANEPLANOCIN A; ADENOSYLHOMOCYSTEINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAT DROPLET; NEPLANOCIN A; TRASTUZUMAB; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE; ADENOSYLHOMOCYSTEINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPLASM; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIPID METABOLISM; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 79954793059     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0982-0     Document Type: Article

References (36)

1. M Esteller 2008 Epigenetics in cancer N Engl J Med 358 1148 1159 18337604 10.1056/NEJMra072067 1:CAS:528:DC%2BD1cXjt1ahs7Y%3D (Pubitemid 351398489)
2. JA Simon CA Lange 2008 Roles of the EZH2 histone methyltransferase in cancer epigenetics Mutat Res Fundam Mol Mech Mutagen 647 21 29 10.1016/j.mrfmmm.2008.07.010 1:CAS:528:DC%2BD1cXhtlyks7nP
3. G Laible A Wolf R Dorn G Reuter C Nislow A Lebersorger D Popkin L Pillus T Jenuwein 1997 Mammalian homologues of the polycomb-group gene enhancer of zeste mediate gene silencing in drosophila heterochromatin and at S. cerevisiae telomeres EMBO J 16 3219 3232 9214638 10.1093/emboj/16.11.3219 1:CAS:528:DyaK2sXktlejs7g%3D (Pubitemid 27234960)
4. DPE Satijn AP Otte 1999 Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochimica et Biophysica Acta (BBA) Gene Struct Expr 1447 1 16 10.1016/S0167-4781(99)00130-X 1:CAS:528: DyaK1MXmtVymsbo%3D (Pubitemid 29433851)
5. C Hwang VN Giri JC Wilkinson CW Wright AS Wilkinson KA Cooney CS Duckett 2008 EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor Breast Cancer Res Treat 107 235 242 17453341 10.1007/s10549-007-9542-7 1:CAS:528:DC%2BD2sXhsVarurvM (Pubitemid 350265691)
6. B Shi J Liang X Yang Y Wang Y Zhao H Wu L Sun Y Zhang Y Chen R Li Y Zhang M Hong Y Shang 2007 Integration of estrogen and Wnt Signaling circuits by the polycomb group protein EZH2 in breast cancer cells Mol Cell Biol 27 5105 5119 17502350 10.1128/MCB.00162-07 1:CAS:528:DC%2BD2sXotFamtbo%3D (Pubitemid 47068285)
7. IH Su M-W Dobenecker E Dickinson M Oser A Basavaraj R Marqueron A Viale D Reinberg C Wülfing A Tarakhovsky 2005 Polycomb group protein Ezh2 controls actin polymerization and cell signaling Cell 121 425 436 15882624 10.1016/j.cell.2005.02.029 1:CAS:528:DC%2BD2MXktlSiu7c%3D (Pubitemid 40692302)
8. T Tonini L Bagella G D'Andrilli PP Claudio A Giordano 2004 Ezh2 reduces the ability of HDAC1-dependent pRb2//p130 transcriptional repression of cyclin A Oncogene 23 4930 4937 15077161 10.1038/sj.onc.1207608 1:CAS:528: DC%2BD2cXkvVOisr4%3D (Pubitemid 38932165)
9. J van der Vlag AP Otte 1999 Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation Nat Genet 23 474 478 10581039 10.1038/70602
10. E Vire C Brenner R Deplus L Blanchon M Fraga C Didelot L Morey A Van Eynde D Bernard JM Vanderwinden M Bollen M Esteller L Di Croce Y de Launoit F Fuks 2006 The polycomb group protein EZH2 directly controls DNA methylation Nature 439 871 874 16357870 10.1038/nature04431 1:CAS:528:DC%2BD28XhsVSkur0%3D (Pubitemid 43255707)
11. IM Bachmann OJ Halvorsen K Collett IM Stefansson O Straume SA Haukaas HB Salvesen AP Otte LA Akslen 2006 EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast J Clin Oncol 24 268 273 16330673 10.1200/JCO.2005.01.5180 1:CAS:528:DC%2BD28XhtVKqtrg%3D (Pubitemid 46622055)
12. AP Bracken D Pasini M Capra E Prosperini E Colli K Helin 2003 EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J 22 5323 5335 14532106 10.1093/emboj/cdg542 1:CAS:528: DC%2BD3sXot1Cqsro%3D (Pubitemid 37279943)
13. K Collett GE Eide J Arnes IM Stefansson J Eide A Braaten T Aas AP Otte LA Akslen 2006 Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer Clin Cancer Res 12 1168 1174 16489070 10.1158/1078-0432.CCR-05- 1533 1:CAS:528:DC%2BD28XhsFalt7c%3D (Pubitemid 43342505)
14. CG Kleer Q Cao S Varambally R Shen I Ota SA Tomlins D Ghosh RG Sewalt AP Otte DF Hayes MS Sabel D Livant SJ Weiss MA Rubin AM Chinnaiyan 2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci USA 100 11606 11611 14500907 10.1073/pnas.1933744100 1:CAS:528:DC%2BD3sXotFKmt7g%3D (Pubitemid 37205983)
15. AM Pietersen HM Horlings M Hauptmann A Langerod A Ajouaou P Cornelissen-Steijger LF Wessels J Jonkers MJ van de Vijver M van Lohuizen 2008 EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer Breast Cancer Res 10 R109 19099573 10.1186/bcr2214
16. T-L Cha BP Zhou W Xia Y Wu C-C Yang C-T Chen B Ping AP Otte M-C Hung 2005 Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3 Science 310 306 310 16224021 10.1126/science.1118947 1:CAS:528:DC%2BD2MXhtV2hurvM (Pubitemid 41457195)
17. D O'Carroll S Erhardt M Pagani SC Barton MA Surani T Jenuwein 2001 The polycomb-group gene Ezh2 is required for early mouse development Mol Cell Biol 21 4330 4336 11390661 10.1128/MCB.21.13.4330-4336.2001 (Pubitemid 32565314)
18. ME Gonzalez X Li K Toy M DuPrie AC Ventura M Banerjee M Ljungman SD Merajver CG Kleer 2009 Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1 Oncogene 28 843 853 19079346 10.1038/onc.2008.433
19. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C (2007) Cancer genetics of epigenetic genes. Hum Mol Genet 16(Spec No 1):R28-R49 (Pubitemid 47241841)
20. E De Clercq 2005 John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity Nucleosides Nucleotides Nucl Acids 24 1395 1415 10.1080/15257770500265638 (Pubitemid 41831807)
21. W Fiskus Y Wang A Sreekumar KM Buckley H Shi A Jillella C Ustun R Rao P Fernandez J Chen R Balusu S Koul P Atadja VE Marquez KN Bhalla 2009 Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells Blood 114 2733 2743 19638619 1:CAS:528:DC%2BD1MXht1eit7jI
22. D Pasini AP Bracken MR Jensen E Lazzerini Denchi K Helin 2004 Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity EMBO J 23 4061 4071 15385962 10.1038/sj.emboj.7600402 1:CAS:528: DC%2BD2cXotlCrs74%3D (Pubitemid 39472427)
23. J Tan X Yang L Zhuang X Jiang W Chen PL Lee RK Karuturi PB Tan ET Liu Q Yu 2007 Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells Genes Dev 21 1050 1063 17437993 10.1101/gad.1524107 1:CAS:528:DC%2BD2sXltFCnsrY%3D (Pubitemid 46686474)
24. TB Miranda CC Cortez CB Yoo G Liang M Abe TK Kelly VE Marquez PA Jones 2009 DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation Mol Cancer Ther 8 1579 1588 19509260 10.1158/1535-7163.MCT-09-0013 1:CAS:528:DC%2BD1MXntVKgtr8%3D
25. X Jiang J Tan J Li S Kivimae X Yang L Zhuang PL Lee MT Chan LW Stanton ET Liu BN Cheyette Q Yu 2008 DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications Cancer Cell 13 529 541 18538736 10.1016/j.ccr.2008.04.019 1:CAS:528:DC%2BD1cXns1yhtbc%3D (Pubitemid 351766796)
26. SJ Crabb M Howell H Rogers M Ishfaq A Yurek-George K Carey BM Pickering P East R Mitter S Maeda PW Johnson P Townsend K Shin-ya M Yoshida A Ganesan G Packham 2008 Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A Biochem Pharmacol 76 463 475 18611394 10.1016/j.bcp.2008.06.004 1:CAS:528:DC%2BD1cXpsVGhsbg%3D
27. G Packham M Brimmell JL Cleveland 1997 Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation Biochem J 328 Pt 3 807 813 9396724 1:CAS:528:DyaK1cXjtVKmug%3D%3D (Pubitemid 28005779)
28. TC Chou 2010 Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res 70 440 446 20068163 10.1158/0008-5472.CAN-09-1947 1:CAS:528:DC%2BC3cXltlWksA%3D%3D
29. SJ Crabb A Hague PW Johnson G Packham 2008 BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells Oncol Rep 19 689 696 18288403 1:CAS:528:DC%2BD1cXjs1elsrg%3D (Pubitemid 351330437)
30. P Greenspan EP Mayer SD Fowler 1985 Nile red: a selective fluorescent stain for intracellular lipid droplets J Cell Biol 100 965 973 3972906 10.1083/jcb.100.3.965 1:CAS:528:DyaL2MXhsVGmtb4%3D (Pubitemid 15135357)
31. PN Munster T Troso-Sandoval N Rosen R Rifkind PA Marks VM Richon 2001 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells Cancer Res 61 8492 8497 11731433 1:CAS:528:DC%2BD3MXptFCkur8%3D (Pubitemid 33131130)
32. L Nolan PW Johnson A Ganesan G Packham SJ Crabb 2008 Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99 689 694 18728657 10.1038/sj.bjc.6604557 1:CAS:528:DC%2BD1cXhtVGgtb7J
33. L Huang AB Pardee 2000 Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment Mol Med 6 849 866 11126200 1:CAS:528:DC%2BD3cXot1WgtL4%3D
34. TH Luu RJ Morgan L Leong D Lim M McNamara J Portnow P Frankel DD Smith JH Doroshow DR Gandara A Aparicio G Somlo C Wong 2008 A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study Clin Cancer Res 14 7138 7142 18981013 10.1158/1078-0432.CCR-08-0122 1:CAS:528:DC%2BD1cXhtlensL7I
35. P Munster D Marchion E Bicaku M Lacevic J Kim B Centeno A Daud A Neuger S Minton D Sullivan 2009 Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC Clin Cancer Res 15 2488 2496 19318486 10.1158/1078-0432.CCR-08-1930 1:CAS:528:DC%2BD1MXjvVWksLo%3D
36. P Bali M Pranpat R Swaby W Fiskus H Yamaguchi M Balasis K Rocha HG Wang V Richon K Bhalla 2005 Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2 Clin Cancer Res 11 6382 6389 16144943 10.1158/1078-0432.CCR-05-0344 1:CAS:528:DC%2BD2MXpslansbk%3D (Pubitemid 41262970)